197 related articles for article (PubMed ID: 38299383)
1. The Parkinson's disease related mutant VPS35 (D620N) amplifies the LRRK2 response to endolysosomal stress.
McCarron KR; Elcocks H; Mortiboys H; Urbé S; Clague MJ
Biochem J; 2024 Feb; 481(4):265-278. PubMed ID: 38299383
[TBL] [Abstract][Full Text] [Related]
2. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
[TBL] [Abstract][Full Text] [Related]
3. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
Kadgien CA; Kamesh A; Milnerwood AJ
Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
[TBL] [Abstract][Full Text] [Related]
4. The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer.
Follett J; Norwood SJ; Hamilton NA; Mohan M; Kovtun O; Tay S; Zhe Y; Wood SA; Mellick GD; Silburn PA; Collins BM; Bugarcic A; Teasdale RD
Traffic; 2014 Feb; 15(2):230-44. PubMed ID: 24152121
[TBL] [Abstract][Full Text] [Related]
5. Formation of retromer transport carriers is disrupted by the Parkinson disease-linked Vps35 D620N variant.
Cui Y; Yang Z; Flores-Rodriguez N; Follett J; Ariotti N; Wall AA; Parton RG; Teasdale RD
Traffic; 2021 Apr; 22(4):123-136. PubMed ID: 33347683
[TBL] [Abstract][Full Text] [Related]
6. Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes.
Wang X; Bondar VV; Davis OB; Maloney MT; Agam M; Chin MY; Cheuk-Nga Ho A; Ghosh R; Leto DE; Joy D; Calvert MEK; Lewcock JW; Di Paolo G; Thorne RG; Sweeney ZK; Henry AG
Elife; 2023 Oct; 12():. PubMed ID: 37874617
[TBL] [Abstract][Full Text] [Related]
7. Retromer binding to FAM21 and the WASH complex is perturbed by the Parkinson disease-linked VPS35(D620N) mutation.
McGough IJ; Steinberg F; Jia D; Barbuti PA; McMillan KJ; Heesom KJ; Whone AL; Caldwell MA; Billadeau DD; Rosen MK; Cullen PJ
Curr Biol; 2014 Jul; 24(14):1670-1676. PubMed ID: 24980502
[TBL] [Abstract][Full Text] [Related]
8. Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites.
Nirujogi RS; Tonelli F; Taylor M; Lis P; Zimprich A; Sammler E; Alessi DR
Biochem J; 2021 Jan; 478(2):299-326. PubMed ID: 33367571
[TBL] [Abstract][Full Text] [Related]
9. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila.
Inoshita T; Arano T; Hosaka Y; Meng H; Umezaki Y; Kosugi S; Morimoto T; Koike M; Chang HY; Imai Y; Hattori N
Hum Mol Genet; 2017 Aug; 26(15):2933-2948. PubMed ID: 28482024
[TBL] [Abstract][Full Text] [Related]
10. Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy.
Zavodszky E; Seaman MN; Moreau K; Jimenez-Sanchez M; Breusegem SY; Harbour ME; Rubinsztein DC
Nat Commun; 2014 May; 5():3828. PubMed ID: 24819384
[TBL] [Abstract][Full Text] [Related]
11. VPS35 and retromer dysfunction in Parkinson's disease.
Rowlands J; Moore DJ
Philos Trans R Soc Lond B Biol Sci; 2024 Apr; 379(1899):20220384. PubMed ID: 38368930
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B.
Pal P; Taylor M; Lam PY; Tonelli F; Hecht CA; Lis P; Nirujogi RS; Phung TK; Yeshaw WM; Jaimon E; Fasimoye R; Dickie EA; Wightman M; Macartney T; Pfeffer SR; Alessi DR
Sci Adv; 2023 Dec; 9(50):eadj1205. PubMed ID: 38091401
[TBL] [Abstract][Full Text] [Related]
13. Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease.
Taylor M; Alessi DR
Curr Opin Cell Biol; 2020 Apr; 63():102-113. PubMed ID: 32036294
[TBL] [Abstract][Full Text] [Related]
14. VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2.
Yun SP; Kim H; Ham S; Kwon SH; Lee GH; Shin JH; Lee SH; Ko HS; Lee Y
Cell Death Dis; 2017 Apr; 8(4):e2741. PubMed ID: 28383562
[TBL] [Abstract][Full Text] [Related]
15. Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2).
Linhart R; Wong SA; Cao J; Tran M; Huynh A; Ardrey C; Park JM; Hsu C; Taha S; Peterson R; Shea S; Kurian J; Venderova K
Mol Neurodegener; 2014 Jun; 9():23. PubMed ID: 24915984
[TBL] [Abstract][Full Text] [Related]
16. The LRRK2-macroautophagy axis and its relevance to Parkinson's disease.
Manzoni C
Biochem Soc Trans; 2017 Feb; 45(1):155-162. PubMed ID: 28202669
[TBL] [Abstract][Full Text] [Related]
17. Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.
Williams ET; Chen X; Otero PA; Moore DJ
Neurobiol Dis; 2022 Aug; 170():105768. PubMed ID: 35588987
[TBL] [Abstract][Full Text] [Related]
18. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 and the Endolysosomal System in Parkinson's Disease.
Erb ML; Moore DJ
J Parkinsons Dis; 2020; 10(4):1271-1291. PubMed ID: 33044192
[TBL] [Abstract][Full Text] [Related]
20. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.
Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S
J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
